As a global leader in urology, we have a rich portfolio of new medicines, considered by some to be among the strongest in the industry.
Urology makes up a significant proportion of primary care consultations.¹ The most common conditions include those that affect bladder and prostate functions.
Astellas has a proven track record in urology. We offer a choice of treatment options for patients with overactive bladder syndrome (OAB), which affects around 17% of people in Europe and can cause urinary incontinence in over a third of patients.² We also have a range of treatments for lower urinary tract symptoms (LUTs) associated with benign prostatic hyperplasia (BPH). LUTs can occur in up to 30% of men over the age of 65 years, and the symptoms they deal with can have a significant impact on their quality of life, one of the most frequent being nocturia (urinary frequency at night).³